M&A / Deals AbbVie climbs post-Allergan M&A peak with Apogee buy PharmaphorumAbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its 'mega-blockbuster' immunology pipeline.Immunology & InflammationRead full story pharminent June 22, 2026 (Last updated: June 22, 2026) Pharmaphorum AbbVie has announced its biggest acquisition since the $63 billion merger with Allergan, buying Apogee and its ‘mega-blockbuster’ immunology pipeline. Immunology & Inflammation Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Lilly bets up to $800M for BioArctic’s brain delivery techNext: AbbVie to Acquire Apogee Therapeutics for Nearly $11 Billion in Immunology Bet Related Stories M&A / Deals Teva and Polpharma Biologics sign global deal for ocrelizumab biosimilar pharminent July 10, 2026 M&A / Deals GSK ends dementia alliance with Alector after setbacks pharminent July 9, 2026 M&A / Deals AstraZeneca, GSK intensify China ties with Sino Biopharm deals pharminent July 8, 2026
